참고문헌
- Atkins MB, Hidalgo M, Stadler WM, et al (2004). Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol, 22, 909-18. https://doi.org/10.1200/JCO.2004.08.185
- Bhargava P, Esteves B, Al-Adhami M, et al (2010). Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): Subgroup analysis from a phase II randomized discontinuation trial (RDT) [abstract 4599]. J Clin Oncol, 28, 366. https://doi.org/10.1200/JCO.2009.26.8292
-
Bracarda S, Bellmunt J, Melichar B, et al (2011). Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-
$\alpha$ 2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial. BJU Int, 107, 214-9. https://doi.org/10.1111/j.1464-410X.2010.09707.x - Brugge JS, MvCormick F (1999). Cell regulation intracellular networking. Curr Opin Cell Biol, 11, 173-6. https://doi.org/10.1016/S0955-0674(99)80022-2
- Bukowski RM (2001). Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol, 19, 148-54.
- Choueiri TK, Pal SK, McDermott DF, et al (2012). Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC). J Clin Oncol, 30, 364. https://doi.org/10.1200/JCO.2012.43.0504
- Drevs J, Muller-Driver R, Wittig C, et al (2002). PTK787/ZK222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res, 62, 4015-22.
- Dutcher JP, de Souza P, McDermott D, et al (2009). Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol, 26, 202-9. https://doi.org/10.1007/s12032-009-9177-0
- Eisen T, Joensuu H, Nathan PD, et al (2012). Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol, 13, 1055-62. https://doi.org/10.1016/S1470-2045(12)70364-9
- Escudier B, Eisen T, Stadler WM, et al (2007). Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 356, 125-34. https://doi.org/10.1056/NEJMoa060655
- Escudier B, Pluzanska A, Koralewski P, et al (2007). Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial. Lancet, 370, 2103-11. https://doi.org/10.1016/S0140-6736(07)61904-7
- Escudier B, Szczylik C, Hutson TE, et al (2009). Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol, 27, 1280-9. https://doi.org/10.1200/JCO.2008.19.3342
- Escudier B, Eisen T, Stadler WM, et al (2009). Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol, 27, 3312-8. https://doi.org/10.1200/JCO.2008.19.5511
- Escudier B, Bellmunt J, Negrier S, et al (2010). Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival. J Clin Oncol, 28, 2144-50. https://doi.org/10.1200/JCO.2009.26.7849
- Escudier B, Kataja V (2010). Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21, 137-9. https://doi.org/10.1093/annonc/mdq206
- Escudier B, Osanto S, Ljungberg B, et al (2012). Multidiciplinary management of metastatic renal cell carcinoma in the era of targeted therapies. Cancer Treat Rev, 38, 127-32. https://doi.org/10.1016/j.ctrv.2011.05.006
- Escudier BJ, Porta C, Bono P, et al (2012). Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a rendomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)- PISCES study, NCT 01064310. J Clin Oncol, 30, 4502.
- Ferrara N, Gerber HP, LeCouter J (2003). The biology of VEGF and its receptors. Nat Med, 9, 669-76. https://doi.org/10.1038/nm0603-669
- Foon KA, Yang XD, Weiner LM, et al (2004). Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys, 58, 984-90. https://doi.org/10.1016/j.ijrobp.2003.09.098
- Frost P, Moatamed F, Hoang B, et al (2004). In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multipl myeloma cells in a xenograft model. Blood, 104, 4181-7. https://doi.org/10.1182/blood-2004-03-1153
- Gore ME, Hariharan S, Porta C, et al (2011). Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer, 117, 501-9. https://doi.org/10.1002/cncr.25452
- Hanna SC, Heatcote SA, Kim WY (2008). mTOR pathway in renal cell carcinoma. Expert Rev Anticancer, 8, 283-92. https://doi.org/10.1586/14737140.8.2.283
- Harari PM (2004). Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer, 11, 689-708. https://doi.org/10.1677/erc.1.00600
- Hicklin DJ, Ellis LM (2005). Role of the vascular endothelial growth factor pathway in tumor-growth and angiogenesis. J Clin Oncol, 23, 1011-27.
- Hudes GR, Carducci M, Tomczak P, et al (2007). Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med, 356, 2271-81. https://doi.org/10.1056/NEJMoa066838
- Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49. https://doi.org/10.3322/caac.20006
- Kuenen BC, Levi M, Meijers JC, et al (2002). Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol, 22, 1500-5. https://doi.org/10.1161/01.ATV.0000030186.66672.36
- Ljungberg B, Campbell SC, Cho HY, et al (2011). The epidemiology of renal cell carcinoma. Eur Urol, 60, 615-21. https://doi.org/10.1016/j.eururo.2011.06.049
- Lundberg AS, Weinberg RA (1999). Control of the cell cycle and apoptosis. Eur J Cancer, 35, 1886-94. https://doi.org/10.1016/S0959-8049(99)00292-0
- Mendel DB, Laird AD, Xin X, et al (2003). In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynmic relationship. Clin Cancer Res, 9, 327-37.
- Mendelsohn J, Baselga J (2003). Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol, 21, 2787-99. https://doi.org/10.1200/JCO.2003.01.504
- Motzer RJ, Mazumdar M, Bacik J, et al (1999). Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol, 17, 2530-40.
- Motzer RJ, Amato R, Todd M, et al (2003). Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs, 21, 99-101. https://doi.org/10.1023/A:1022928612511
- Motzer RJ, Bacik J, Schwartz LH, et al (2004). Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol, 22, 454-63.
- Motzer RJ, Rini BI, Bukowski RM, et al (2006). Sunitinib in patients with metastatic renal cell carcinoma. JAMA, 295, 2516-24. https://doi.org/10.1001/jama.295.21.2516
- Motzer RJ, Michaelson MD, Redman BG, et al (2006). Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol, 24, 16-24. https://doi.org/10.1200/JCO.2005.02.2574
- Motzer RJ, Hutson TE, Tomczak P, et al (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 356, 115-24. https://doi.org/10.1056/NEJMoa065044
- Motzer RJ, Escudier B, Oudard S, et al (2008). Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomized, placebo-controlled phase III trial. Lancet, 72, 449-56.
- Motzer RJ, Escudier B, Oudard S, et al (2010). Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer, 116, 4256-65. https://doi.org/10.1002/cncr.25219
- Motzer RJ, Hutson TE, Olsen MR, et al (2011). Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial. J Clin Oncol, 29, 308. https://doi.org/10.1200/JCO.2010.32.6082
- Motzer RJ, Hudson TE, Reeves J, et al (2012). Randomized, open-label, phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (mrcc): results of the COMPARZ trial. Presented at: 2012 European Society for Medical Oncology; Vienna, Austria; October 1, 20120. Abstract LBA 8. ESMO.
- Motzer RJ, Nosov D, Eisen T, et al (2012). Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial. J Clin Oncol, 30, 4501. https://doi.org/10.1200/JCO.2012.43.6758
- Negrier S, Gravis G, Perol D, et al (2011). Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomized phase 2 trial. Lancet Oncol, 12, 673-80. https://doi.org/10.1016/S1470-2045(11)70124-3
- Presta LG, Chen H, O'Connor SJ, et al (1997). Humanization of an anti-vascular endothelian growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res, 57, 4593-9.
- Price JT, Wilson HM, Haites NE (1996). Epidermal growth factor (EGF) increases the in vitro invasion, motility, and adhesion interactions of the primary renal carcinoma cell line, A704. Eur J Cancer, 32, 1977-82. https://doi.org/10.1016/0959-8049(96)00207-9
- Radulovic S, Bjelogrlic SK (2007). Sunitinib, sorafenib and mTOR inhibitors in renal cancer. J BUON, 12, 151-62.
- Ratain MJ, Eisen T, Stadler WM, et al (2006). Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol, 24, 2505-12. https://doi.org/10.1200/JCO.2005.03.6723
- Rini B (2005). SU11248 and AG013736: current data and future trials in renal cell carcinoma. Clin Genitourin Cancer, 4, 175-80. https://doi.org/10.3816/CGC.2005.n.029
- Rini B (2007). Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res, 13, 1098-106. https://doi.org/10.1158/1078-0432.CCR-06-1989
- Rini B, Escudier B, Tomczak P, et al (2011). Axitinib vs sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase III AXIS trial. ASCO 2011 [abstract:4503].
- Rini BI (2005). VEGF-targeted therapy in metastatic renal cell carcinoma. Oncologist, 10, 191-7. https://doi.org/10.1634/theoncologist.10-3-191
- Rini BI, Halabi S, Rosenberg JE, et al (2008). Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with renal cell carcinoma: CALGB 90206. J Clin Oncol, 26, 5422-8. https://doi.org/10.1200/JCO.2008.16.9847
- Rini BI, Halabi S, Rosenberg JE, et al (2010). Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monothreapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol, 28, 2137-43. https://doi.org/10.1200/JCO.2009.26.5561
- Rini BI, Escudier B, Tomczak P, et al (2011). Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial. Lancet, 378, 1931-9. https://doi.org/10.1016/S0140-6736(11)61613-9
- Rini BI, Grunwald V, Fishman MN, et al (2012). Axitinib for first-line metastatic renal cell carcinoma (mRCC): Overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study. J Clin Oncol, 30, 4503.
- Sternberg CN, Davis ID, Mardiak J, et al (2010). Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol, 28, 1061-68. https://doi.org/10.1200/JCO.2009.23.9764
- Xu L, Tong R, Cochran DM, et al (2005). Blocking platelet-derived growth factor-D/ platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res, 65, 5711-19. https://doi.org/10.1158/0008-5472.CAN-04-4313
- Wells A (1999). EGF receptor. Int J Biochem Cell Biol, 31, 637-43. https://doi.org/10.1016/S1357-2725(99)00015-1
- Willhelm SM, Carter C, Tang L, et al (2004). BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEF/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 64, 7099-109. https://doi.org/10.1158/0008-5472.CAN-04-1443
- Yang JC, Haworth L, Sherry RM, et al (2003). A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med, 349, 427-34. https://doi.org/10.1056/NEJMoa021491
- Yazici S, Kiziloz H, Ozen H (2011). Recent advancements in the targeted therapy of metastatic kidney cancer. Uroonkoloji Bulteni, 3, 41-51.
피인용 문헌
- Asparagus Racemosus Leaf Extract Inhibits Growth of UOK 146 Renal Cell Carcinoma Cell Line: Simultaneous Oncogenic PRCCTFE3 Fusion Transcript Inhibition and Apoptosis Independent Cell Death vol.15, pp.5, 2014, https://doi.org/10.7314/APJCP.2014.15.5.1937
- Targeting EGFL7 Expression through RNA Interference Suppresses Renal Cell Carcinoma Growth by Inhibiting Angiogenesis vol.15, pp.7, 2014, https://doi.org/10.7314/APJCP.2014.15.7.3045
- ST6Gal-I Predicts Postoperative Clinical Outcome for Patients with Localized Clear-cell Renal Cell Carcinoma vol.15, pp.23, 2014, https://doi.org/10.7314/APJCP.2014.15.23.10217
- Phosphorylated Signal Transducer and Activator of Transcription 1 is a potential predictor of interferon response in patients with advanced renal cell carcinoma vol.9, pp.5, 2014, https://doi.org/10.3892/mmr.2014.2046